FMA Advisory’s AstraZeneca AZN Stock Holding History

FMA Advisory’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$20K	Buy	+320	New	+$21.9K	0.01%	248

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

FMA Advisory's AZN Position: Q2 2015 in Review

FMA Advisory opened a new position in AstraZeneca (AZN) in Q2 2015: 320 shares worth $20K. The stake represents 0.01% of the portfolio and ranks #248 among its holdings.

375 funds tracked by Wall St. Rank hold AZN as of Q2 2015.

FMA Advisory held 320 shares of AstraZeneca worth $20K as of Q2 2015.
AstraZeneca was a new FMA Advisory position in Q2 2015.
AstraZeneca made up 0.01% of FMA Advisory's portfolio in Q2 2015, its #248 holding.
375 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2015.

Based on FMA Advisory's 13F filing for Q2 2015, filed 17 Dec 2019.